/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Adaptive Biotechnologies Corp

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$17.47 -0.0835(-8.35%) ADPT at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 16.5
Highest Today 18.7
Today’s Open 18.7
Prev. Close 18.69
52 Week High 20.76
52 Week Low 5.81
Day’s Range: Low 16.5 High 18.7
52-Week Range: Low 5.81 High 20.76
1 day return -
1 Week return -12.34
1 month return +1.03
3 month return +31.5
6 month return +71.49
1 year return +179.2
3 year return +107.45
5 year return -64.17
10 year return -

Institutional Holdings

Viking Global Investors LP 19.70

BlackRock Inc 8.98

Vanguard Group Inc 7.41

Rubric Capital Management LP 4.11

Vanguard Total Stock Mkt Idx Inv 2.89

Amova Asset Management Americas, Inc 2.82

Sumitomo Mitsui Trust Group Inc 2.82

ARK Investment Management LLC 2.64

ARK Genomic Revolution 2.58

BRAIDWELL LP 2.54

iShares Russell 2000 ETF 2.37

Amova ARK Pstv Chg Innovt P JPY Acc 2.20

Columbia Cornerstone Growth SMA 2.14

Ameriprise Financial Inc 2.13

ARK Genomic Revolution ETF 2.13

Geode Capital Management, LLC 2.11

State Street Corp 1.99

Aristotle Atlantic Partners, LLC 1.89

Driehaus Capital Management LLC 1.59

Fred Alger Management, LLC 1.55

Columbia Small Cap Growth Inst 1.44

Blue Water Life Science Advisors, LLC 1.41

Columbia Small Cap Growth 1.31

Goldman Sachs Group Inc 1.27

Bank of America Corp 1.22

Vanguard Small Cap Index 1.15

Victory Capital Management Inc. 1.12

Alger Small Cap Focus Composite 1.07

Alger Small Cap Focus I 1.07

Aristotle Atlantic Focus Growth Equity 1.06

ING Investment Management LLC 1.02

Fidelity Small Cap Index 0.98

Iron Triangle Partners LP 0.98

iShares Russell 2000 Growth ETF 0.86

Vanguard Institutional Extnd Mkt Idx Tr 0.81

Vanguard Small Cap Growth Index Inv 0.64

MFS New Discovery I 0.64

Nuveen Quant Small Cap Equity R6 0.58

iShares Biotechnology ETF 0.57

Columbia Acorn Inst 0.56

Market Status

Strong Buy: 3

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 2853.31 M

PB Ratio 14.6814

PE Ratio 0.0

Enterprise Value 2870.43 M

Total Assets 539.38 M

Volume 4712963

Company Financials

Annual Revenue FY23:179690000 179.7M, FY22:185308000 185.3M, FY21:154344000 154.3M, FY20:98382000 98.4M, FY19:85071000 85.1M

Annual Profit FY23:107164000 107.2M, FY22:127399000 127.4M, FY21:105043000 105.0M, FY20:75852000 75.9M, FY19:62797000 62.8M

Annual Net worth FY23:-195937000 -195.9M, FY22:-142464000 -142.5M, FY21:-205611000 -205.6M, FY20:-139637000 -139.6M, FY19:-58821000 -58.8M

Quarterly Revenue Q3/2025:93973000 94.0M, Q2/2025:58879000 58.9M, Q1/2025:52443000 52.4M, Q3/2024:46435000 46.4M, Q2/2024:43190000 43.2M

Quarterly Profit Q3/2025:75816000 75.8M, Q2/2025:40880000 40.9M, Q1/2025:35464000 35.5M, Q3/2024:29768000 29.8M, Q2/2024:21088000 21.1M

Quarterly Net worth Q3/2025:9546000 9.5M, Q2/2025:-25614000 -25.6M, Q1/2025:-29852000 -29.9M, Q3/2024:-32071000 -32.1M, Q2/2024:-46222000 -46.2M

Fund house & investment objective

Company Information Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Organisation Biotechnology

Employees 619

Industry Biotechnology

CEO Mr. Chad M. Robins M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow